Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone acetate in hormone-refractory prostate cancer after hormone therapy failure
2005-001166-13Phase 2Completed
- Sponsor
- Cougar Biotechnology
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abiraterone in castration-resistant prostate cancer (CRPC), sponsored by Cougar Biotechnology. Primary endpoints: Confirmed PSA response, PSA decline greater than 50% and 1 more. Started Aug 2005; status: completed.
02
Drugs
abiraterone
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2005-001166-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001166-13.